It belongs to a class known as GLP-1 receptor agonists, which work by mimicking the action of the glucagon-like peptide-1 hormone
You can take other Results RNA formulas immediately
#PharmD #clinicalpharmacy #Drugupdate #Obesitymanagement To view or add a comment, sign in Obesity Market is Expected to Witness Significant Growth by 2036 Due to Advancements in GLP-1 Therapies and Expanding Treatment Accessibility | DelveInsight: The obesity market is experiencing substantial transformation driven by the rising global obesity burden, growing awareness regarding obesity as a chronic disease, increasing adoption of GLP-1 receptor agonists, and the emergence of next-generation metabolic therapies
GLP-1 acts on pancreatic cells by inhibiting the alpha cells responsible for glucagon secretion [30] and stimulating insulin production in beta cells in response to elevated blood glucose levels [23]
Little enhancement of meal-induced glucagon-like peptide 1 secretion in Japanese: Comparison of type 2 diabetes patients and healthy controls
Even with these lower net prices, over 10 years for obesity coverage, HHS estimated: -$24.8B in new Medicare spending -$11B in federal Medicaid spending -$3.8B in state Medicaid spending --- How do net prices impact the markets consideration for GLP-1 coverage and access